Fig. 3From: A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22 a Schedule A heat map of patient gene expression data. b Schedule B heat map of patient gene expression dataBack to article page